Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Liquidia CorpLQDA · Entity 1860 | Chief Medical Officer | October 09, 2026 | October 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Liquidia Corp
Report date October 09, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 126,368 |
Last balance in matching sequence
After 2026-10-12 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2026-10-09 · Exercise / conversion · Acquired 3,530 · Balance 131,100 F2: On January 11, 2024, the Reporting Person was granted 56,492 PSUs which vest upon the following time-based vesting schedule: 25% of the PSUs shall vest on January 11, 2025 and the remaining PSUs shall vest ratably on a quarterly basis over three years thereafter. Of those PSUs, a total of 38,838 have vested as of the date of this Form 4. F1: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F3: Includes (i) 5,208 unvested restricted stock units ("RSUs") of the 83,333 RSUs granted to the Reporting Person on January 11, 2023, (ii) 17,654 unvested RSUs of the 56,492 RSUs granted to the Reporting Person on January 11, 2024, (iii) 40,376 unvested RSUs of the 71,780 RSUs granted to the Reporting Person on January 11, 2025, (iv) 32,955 RSUs granted to the Reporting Person on January 16, 2026, none of which have vested as of the date of this Form 4 and (v) 3,054 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan. Row 2 · 2026-10-09 · Exercise / conversion · Acquired 4,486 · Balance 135,586 F4: On January 11, 2025, the Reporting Person was granted 71,780 PSUs which vest upon the following time-based vesting schedule: 25% of the PSUs shall vest on January 11, 2026 and the remaining PSUs shall vest ratably on a quarterly basis over three years thereafter. Of those PSUs, a total of 31,404 have vested as of the date of this Form 4. F1: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F3: Includes (i) 5,208 unvested restricted stock units ("RSUs") of the 83,333 RSUs granted to the Reporting Person on January 11, 2023, (ii) 17,654 unvested RSUs of the 56,492 RSUs granted to the Reporting Person on January 11, 2024, (iii) 40,376 unvested RSUs of the 71,780 RSUs granted to the Reporting Person on January 11, 2025, (iv) 32,955 RSUs granted to the Reporting Person on January 16, 2026, none of which have vested as of the date of this Form 4 and (v) 3,054 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan. Row 3 · 2026-10-12 · Sale · Disposed 9,218 · Balance 126,368 F5: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023. F6: These shares of common stock were sold to cover taxes associated with the settlement of RSUs and PSUs that were initially granted to the Reporting Person on January 11, 2023, January 11, 2024 and January 11, 2025. F1: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. F3: Includes (i) 5,208 unvested restricted stock units ("RSUs") of the 83,333 RSUs granted to the Reporting Person on January 11, 2023, (ii) 17,654 unvested RSUs of the 56,492 RSUs granted to the Reporting Person on January 11, 2024, (iii) 40,376 unvested RSUs of the 71,780 RSUs granted to the Reporting Person on January 11, 2025, (iv) 32,955 RSUs granted to the Reporting Person on January 16, 2026, none of which have vested as of the date of this Form 4 and (v) 3,054 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 17,654 |
Reported balance
After 2026-10-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-10-09 · Exercise / conversion · Disposed 3,530 · Balance 17,654 F1: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 40,376 |
Reported balance
After 2026-10-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-10-09 · Exercise / conversion · Disposed 4,486 · Balance 40,376 F1: Performance stock units ("PSUs") convert into common stock on a one-for-one basis. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 15,099 |
Reported balance
Holding disclosure · report date 2026-10-09 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 15,099 F7: The securities are held by Saggar Legacy Trust ("Trust"). The Reporting Person is the trustee of the Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Performance stock units ("PSUs") convert into common stock on a one-for-one basis.
F2: On January 11, 2024, the Reporting Person was granted 56,492 PSUs which vest upon the following time-based vesting schedule: 25% of the PSUs shall vest on January 11, 2025 and the remaining PSUs shall vest ratably on a quarterly basis over three years thereafter. Of those PSUs, a total of 38,838 have vested as of the date of this Form 4.
F3: Includes (i) 5,208 unvested restricted stock units ("RSUs") of the 83,333 RSUs granted to the Reporting Person on January 11, 2023, (ii) 17,654 unvested RSUs of the 56,492 RSUs granted to the Reporting Person on January 11, 2024, (iii) 40,376 unvested RSUs of the 71,780 RSUs granted to the Reporting Person on January 11, 2025, (iv) 32,955 RSUs granted to the Reporting Person on January 16, 2026, none of which have vested as of the date of this Form 4 and (v) 3,054 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan.
F4: On January 11, 2025, the Reporting Person was granted 71,780 PSUs which vest upon the following time-based vesting schedule: 25% of the PSUs shall vest on January 11, 2026 and the remaining PSUs shall vest ratably on a quarterly basis over three years thereafter. Of those PSUs, a total of 31,404 have vested as of the date of this Form 4.
F5: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023.
F6: These shares of common stock were sold to cover taxes associated with the settlement of RSUs and PSUs that were initially granted to the Reporting Person on January 11, 2023, January 11, 2024 and January 11, 2025.
F7: The securities are held by Saggar Legacy Trust ("Trust"). The Reporting Person is the trustee of the Trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 12, 2024 Filed Jul 15, 2024 22:25 UTC | Liquidia Corp LQDA · Entity 1860 | SaleCommon Stock | 1,470 | $12.53 | $18,419.10 |
DisclosureSEC source: 0001104659-24-079924 · tm2419492-2_4seq1.xml · nonDerivative · entry 1 Saggar Rajeev · CIK 0001935638 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,202 F1 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023. F2 · shares: These shares of common stock were sold to cover taxes associated with the settlement of restricted stock units ("RSUs") that were initially granted to the Reporting Person on January 11, 2023. F3 · balance_after: Includes (i) 29,323 unvested RSUs of the 93,834 RSUs granted to the Reporting Person on July 18, 2022, (ii) 52,082 unvested RSUs of the 83,333 RSUs granted to the Reporting Person on January 11, 2023, (iii) 56,492 RSUs granted to the Reporting Person on January 11, 2024, none of which have vested as of the date of this Form 4 and (iv) 3,604 shares of common stock acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan. Read SEC document |
| April 19, 2024 Filed Apr 23, 2024 21:24 UTC | Liquidia Corp LQDA · Entity 1860 | SaleCommon Stock | 1,649 | $13.68 | $22,558.32 |
DisclosureSEC source: 0001104659-24-050664 · tm2411915-7_4seq1.xml · nonDerivative · entry 1 Saggar Rajeev · CIK 0001935638 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 211,672 F1 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023. F2 · shares: These shares of common stock were sold to cover taxes associated with the settlement of restricted stock units ("RSUs") that were initially granted to the Reporting Person on July 18, 2022. F3 · balance_after: Includes (i) 29,323 unvested RSUs of the 93,834 RSUs granted to the Reporting Person on July 18, 2022, (ii) 57,291 unvested RSUs of the 83,333 RSUs granted to the Reporting Person on January 11, 2023, (iii) 56,492 RSUs granted to the Reporting Person on January 11, 2024, none of which have vested as of the date of this Form 4 and (iv) 3,604 shares of common stock acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan. Read SEC document |
| April 12, 2024 Filed Apr 16, 2024 21:17 UTC | Liquidia Corp LQDA · Entity 1860 | SaleCommon Stock | 1,525 | $14.58 | $22,234.50 |
DisclosureSEC source: 0001104659-24-047891 · tm2411915-5_4seq1.xml · nonDerivative · entry 1 Saggar Rajeev · CIK 0001935638 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,321 F1 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023. F2 · shares: These shares of common stock were sold to cover taxes associated with the settlement of restricted stock units ("RSUs") that were initially granted to the Reporting Person on January 11, 2023. F3 · balance_after: Includes (i) 35,188 unvested RSUs of the 93,834 RSUs granted to the Reporting Person on July 18, 2022, (ii) 57,291 unvested RSUs of the 83,333 RSUs granted to the Reporting Person on January 11, 2023, (iii) 56,492 RSUs granted to the Reporting Person on January 11, 2024, none of which have vested as of the date of this Form 4 and (iv) 3,604 shares of common stock acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 01:46 UTC | Liquidia Corp LQDA · Entity 1860 | SaleCommon Stock | 5,876 | $15.82 | $92,958.32 |
DisclosureSEC source: 0001104659-24-036346 · tm247887-6_4seq1.xml · nonDerivative · entry 2 Saggar Rajeev · CIK 0001935638 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 214,846 F1 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023. F3 · shares: These shares of common stock were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on January 11, 2023. F4 · balance_after: Includes (i) 40,638 unvested RSUs of the 93,834 RSUs granted to the Reporting Person on July 18, 2022, (ii) 62,499 unvested RSUs of the 83,333 RSUs granted to the Reporting Person on January 11, 2023, (iii) 56,492 RSUs granted to the Reporting Person on January 11, 2024, none of which have vested as of the date of this Form 4 and (iv) 3,604 shares of common stock acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 01:46 UTC | Liquidia Corp LQDA · Entity 1860 | SaleCommon Stock | 1,654 | $15.82 | $26,166.28 |
DisclosureSEC source: 0001104659-24-036346 · tm247887-6_4seq1.xml · nonDerivative · entry 1 Saggar Rajeev · CIK 0001935638 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 220,722 F1 · kind: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023. F2 · shares: These shares of common stock were sold to cover taxes associated with the settlement of restricted stock units ("RSUs") that were initially granted to the Reporting Person on July 28, 2022. F4 · balance_after: Includes (i) 40,638 unvested RSUs of the 93,834 RSUs granted to the Reporting Person on July 18, 2022, (ii) 62,499 unvested RSUs of the 83,333 RSUs granted to the Reporting Person on January 11, 2023, (iii) 56,492 RSUs granted to the Reporting Person on January 11, 2024, none of which have vested as of the date of this Form 4 and (iv) 3,604 shares of common stock acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan. Read SEC document |
| January 11, 2024 Filed Jan 16, 2024 22:03 UTC | Liquidia Corp LQDA · Entity 1860 | GrantPerformance Stock Units · Derivative | 56,492 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-004155 · tm243427-5_4seq1.xml · derivative · entry 2 Saggar Rajeev · CIK 0001935638 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,492 Underlying: Common Stock · 56,492 shares Expires not disclosed F4 · derivative.exercise_price: Each performance stock unit ("PSU") converts into one share of the Issuer's common stock. F5 · derivative.exercise_date: On January 11, 2024, the Reporting Person was granted 56,492 PSUs. The PSUs shall vest upon the later of (A) the following time-based vesting schedule: 25% of the PSUs shall vest on January 11, 2025 and the remaining PSUs shall vest ratably on a quarterly basis over three years thereafter and (B) the first commercial sale of YUTREPIA by the Issuer. F5 · derivative.expiration_date: On January 11, 2024, the Reporting Person was granted 56,492 PSUs. The PSUs shall vest upon the later of (A) the following time-based vesting schedule: 25% of the PSUs shall vest on January 11, 2025 and the remaining PSUs shall vest ratably on a quarterly basis over three years thereafter and (B) the first commercial sale of YUTREPIA by the Issuer. Read SEC document |
| January 11, 2024 Filed Jan 16, 2024 22:03 UTC | Liquidia Corp LQDA · Entity 1860 | GrantCommon Stock | 56,492 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-004155 · tm243427-5_4seq1.xml · nonDerivative · entry 1 Saggar Rajeev · CIK 0001935638 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,591 F1 · kind: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: 25% of the RSUs shall vest on January 11, 2025 and the remaining RSUs shall vest ratably on a quarterly basis over three years thereafter. F3 · balance_after: Includes (i) 46,052 unvested RSUs of the 93,834 RSUs granted to the Reporting Person on July 18, 2022, (ii) 83,333 RSUs granted to the Reporting Person on January 11, 2023 and (iii) 1,189 shares of common stock acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan. Read SEC document |
| December 18, 2023 Filed Dec 19, 2023 01:58 UTC | Liquidia Corp LQDA · Entity 1860 | SaleCommon Stock | 14,887 | $7.42 | $110,461.54 |
DisclosureSEC source: 0001104659-23-127037 · tm2332275-7_4seq1.xml · nonDerivative · entry 1 Saggar Rajeev · CIK 0001935638 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,099 F1 · shares: On July 18, 2022, the Reporting Person was awarded an aggregate of 93,834 restricted stock units ("RSUs"), all of which, including the unvested portion, were reported on a Form 4 filed on July 20, 2022. The vesting of 52,782 of those previously reported RSUs was deferred until December 14, 2023. As reported on this Form 4, only the requisite amount of shares were sold to cover the required taxes in connection with the vesting and settlement of the 52,782 previously reported RSUs. F2 · balance_after: Includes (i) 93,384 RSUs granted to the Reporting Person on July 18, 2022, of which 52,782 have vested as of the date of this Form 4, (ii) 83,333 RSUs granted to the Reporting Person on January 11, 2023, none of which have vested as of the date of this Form 4 and (iii) 1,819 shares of common stock acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan on August 31, 2023. Read SEC document |
| January 11, 2023 Filed Jan 13, 2023 22:18 UTC | Liquidia Corp LQDA · Entity 1860 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 106,838 | $0.00 Strike: $6.17 | $0.00 |
DisclosureSEC source: 0001104659-23-003883 · tm232332-6_4seq1.xml · derivative · entry 2 Saggar Rajeev · CIK 0001935638 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,838 Underlying: Common Stock · 106,838 shares Expires 2033-01-11 F3 · derivative.exercise_date: The options will vest ratably on a monthly basis over four years with the first vesting date to occur on February 11, 2023 and on the last day of each month thereafter. Read SEC document |
| January 11, 2023 Filed Jan 13, 2023 22:18 UTC | Liquidia Corp LQDA · Entity 1860 | GrantCommon Stock | 83,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-003883 · tm232332-6_4seq1.xml · nonDerivative · entry 1 Saggar Rajeev · CIK 0001935638 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,167 F1 · kind: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: 25% of the RSUs shall vest on January 11, 2024 and the remaining RSUs shall vest ratably on a quarterly basis over three years thereafter. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 20:31 UTC | Liquidia Corp LQDA · Entity 1860 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $3.73 | $0.00 |
DisclosureSEC source: 0001104659-22-081182 · tm2221469-2_4seq1.xml · derivative · entry 2 Saggar Rajeev · CIK 0001935638 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-07-18 F3 · derivative.exercise_date: The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter, subject to the Reporting Person's employment with the Issuer on each such vesting date. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 20:31 UTC | Liquidia Corp LQDA · Entity 1860 | GrantCommon Stock | 93,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-081182 · tm2221469-2_4seq1.xml · nonDerivative · entry 1 Saggar Rajeev · CIK 0001935638 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,834 F1 · kind: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: 50% of the RSUs shall vest on July 18, 2023 and the remaining RSUs shall vest ratably on a quarterly basis over two years thereafter, subject to the Reporting Person's employment with the Issuer on each such vesting date; provided, however, that the RSUs shall become fully vested in the event that the Reporting Person's employment is terminated due to his death or Disability or is terminated by the Company without Cause (as such terms are defined in the Reporting Person's Employment Agreement). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.